```

[House Report 115-329]
[From the U.S. Government Publishing Office]

115th Congress    }                                    {        Report
                        HOUSE OF REPRESENTATIVES
 1st Session      }                                    {       115-329

======================================================================

 
          CONGENITAL HEART FUTURES REAUTHORIZATION ACT OF 2017

                                _______
                                

 September 25, 2017.--Committed to the Committee of the Whole House on 
            the State of the Union and ordered to be printed

                                _______
                                

        Mr. Walden, from the Committee on Energy and Commerce, 
                        submitted the following

                              R E P O R T

                        [To accompany H.R. 1222]

      [Including cost estimate of the Congressional Budget Office]

    The Committee on Energy and Commerce, to whom was referred 
the bill (H.R. 1222) to amend the Public Health Service Act to 
coordinate Federal congenital heart disease research efforts 
and to improve public education and awareness of congenital 
heart disease, and for other purposes, having considered the 
same, report favorably thereon with an amendment and recommend 
that the bill as amended do pass.

                                CONTENTS

                                                                   Page
Purpose and Summary..............................................     3
Background and Need for Legislation..............................     3
Committee Action.................................................     3
Committee Votes..................................................     4
Oversight Findings and Recommendations...........................     4
New Budget Authority, Entitlement Authority, and Tax Expenditures     4
Congressional Budget Office Estimate.............................     4
Federal Mandates Statement.......................................     6
Statement of General Performance Goals and Objectives............     6
Duplication of Federal Programs..................................     6
Committee Cost Estimate..........................................     6
Earmark, Limited Tax Benefits, and Limited Tariff Benefits.......     6
Disclosure of Directed Rule Makings..............................     7
Advisory Committee Statement.....................................     7
Applicability to Legislative Branch..............................     7
Section-by-Section Analysis of the Legislation...................     7
Changes in Existing Law Made by the Bill, as Reported............     7

    The amendment is as follows:
  Strike all after the enacting clause and insert the 
following:

SECTION 1. SHORT TITLE.

  This Act may be cited as the ``Congenital Heart Futures 
Reauthorization Act of 2017''.

SEC. 2. NATIONAL CONGENITAL HEART DISEASE SURVEILLANCE SYSTEM.

  Section 399V-2 of the Public Health Service Act (42 U.S.C. 280g-13) 
is amended to read as follows:

``SEC. 399V-2. NATIONAL CONGENITAL HEART DISEASE RESEARCH, 
                    SURVEILLANCE, AND AWARENESS.

  ``(a) In General.--The Secretary shall--
          ``(1) enhance and expand research and surveillance 
        infrastructure to study and track the epidemiology of 
        congenital heart disease (in this section referred to as 
        `CHD'); and
          ``(2) award grants to eligible entities to undertake the 
        activities described in this section.
  ``(b) National Congenital Heart Disease Study.--
          ``(1) In general.--The Secretary shall plan, develop, 
        implement, and submit one or more reports to the Congress on a 
        study to improve understanding of the epidemiology of CHD 
        across the lifespan, from birth to adulthood, with particular 
        interest in the following:
                  ``(A) Health care utilization of those affected by 
                CHD.
                  ``(B) Demographic factors associated with CHD, such 
                as age, race, ethnicity, gender, and family history of 
                individuals who are diagnosed with the disease.
                  ``(C) Outcome measures, such that analysis of the 
                outcome measures will allow derivation of evidence-
                based best practices and guidelines for CHD patients.
          ``(2) Permissible considerations.--The study under this 
        subsection may--
                  ``(A) gather data on the health outcomes of a diverse 
                population of those affected by CHD;
                  ``(B) consider health disparities among those 
                affected by CHD, which may include the consideration of 
                prenatal exposures; and
                  ``(C) incorporate behavioral, emotional, and 
                educational outcomes of those affected by CHD.
          ``(3) Public access.--Data generated from the study under 
        this subsection shall be made available--
                  ``(A) for purposes of CHD research, subject to 
                appropriate protections of personal privacy, including 
                protections required by paragraph (4); and
                  ``(B) to the public, subject to paragraph (4) and 
                with appropriate exceptions for protection of personal 
                privacy.
          ``(4) Patient privacy.--The Secretary shall ensure that the 
        study under this subsection is carried out in a manner that 
        complies with the requirements applicable to a covered entity 
        under the regulations promulgated pursuant to section 264(c) of 
        the Health Insurance Portability and Accountability Act of 
        1996.
  ``(c) Eligibility for Grants.--To be eligible to receive a grant 
under subsection (a)(2), an entity shall--
          ``(1) be a public or private nonprofit entity with 
        specialized experience in CHD; and
          ``(2) submit to the Secretary an application at such time, in 
        such manner, and containing such information as the Secretary 
        may require.
  ``(d) Authorization of Appropriations.--To carry out this section, 
there is authorized to be appropriated $4,000,000 for each of fiscal 
years 2018 through 2022.''.

SEC. 3. CONGENITAL HEART DISEASE RESEARCH.

  Section 425 of the Public Health Service Act (42 U.S.C. 285b-8) is 
amended to read as follows:

``SEC. 425. CONGENITAL HEART DISEASE.

  ``(a) In General.--The Director of the Institute may expand, 
intensify, and coordinate research and related activities of the 
Institute with respect to congenital heart disease, which may include 
congenital heart disease research with respect to--
          ``(1) causation of congenital heart disease, including 
        genetic causes;
          ``(2) long-term outcomes in individuals with congenital heart 
        disease, including infants, children, teenagers, adults, and 
        elderly individuals;
          ``(3) diagnosis, treatment, and prevention;
          ``(4) studies using longitudinal data and retrospective 
        analysis to identify effective treatments and outcomes for 
        individuals with congenital heart disease; and
          ``(5) identifying barriers to lifelong care for individuals 
        with congenital heart disease.
  ``(b) Coordination of Research Activities.--The Director of the 
Institute may coordinate research efforts related to congenital heart 
disease among multiple research institutions and may develop research 
networks.
  ``(c) Minority and Medically Underserved Communities.--In carrying 
out the activities described in this section, the Director of the 
Institute shall consider the application of such research and other 
activities to minority and medically underserved communities.
  ``(d) Report From NIH.--Not later than one year after the date of the 
enactment of the Congenital Heart Futures Reauthorization Act of 2017, 
the Director of NIH, acting through the Director of the Institute, 
shall provide a report to Congress--
          ``(1) outlining the ongoing research efforts of the National 
        Institutes of Health regarding congenital heart disease; and
          ``(2) identifying--
                  ``(A) future plans for research regarding congenital 
                heart disease; and
                  ``(B) the areas of greatest need for such 
                research.''.

                          Purpose and Summary

    H.R. 1222 was introduced on May 11, 2017, by Rep. Gus 
Bilirakis (R-FL). The bill reauthorizes research and 
surveillance efforts to study and track congenital heart 
disease (CHD). It enhances current activities at the Centers 
for Disease Control and Prevention, awards grants to further 
study CHD, and directs the National Institutes of Health to 
report on their ongoing research efforts in this space.

                  Background and Need for Legislation

    Congenital heart diseases (CHDs) are defects in the 
structure and function of the heart that disrupt the flow of 
blood through the heart. These defects range from simple to 
severe and life threatening. CHDs are the most common birth 
defect and the leading cause of infant mortality. Although the 
causes of CHDs among most infants are unknown, according to the 
CDC, at least 15 percent of all CHDs are associated with 
genetic conditions. Indeed, CHD is prevalent in individuals 
with Down syndrome; approximately half of all infants born with 
Down syndrome have cardiovascular defects.
    Although advances in medical care permit adults and 
children with CHD to lead longer and healthier lives, disease 
management--especially in critical cases--still requires a 
lifetime of specialized cardiac care. Accurately tracking the 
prevalence, further understanding the causes, and identifying 
novel treatments will improve the lives of those living with 
CHD and decrease the risk of birth defects in the future.

                            Committee Action

    During the 114th Congress, on September 8, 2016, the 
Subcommittee on Health held a hearing on H.R. 3952, which was 
substantially similar to H.R. 1222. The hearing was entitled 
``Examining Legislation to Improve Public Health.'' The 
Subcommittee received testimony from:
           Sonja L. Banks, President and COO, Sickle 
        Cell Disease Association of America, Inc.;
           General Arthur Dean, Chairman and CEO, 
        Community Anti-Drug Coalitions of America;
           Jonathan Leffert, President-Elect, American 
        Association of Clinical Endocrinologists;
           Brad Marino, Chair, Pediatric Congenital 
        Heart Association; and
           R. Sean Morrison, Director, National 
        Palliative Care Research Center.
    On May 18, 2017, the Subcommittee on Health met in open 
markup session and forwarded H.R. 1222, as amended, to the full 
Committee by a voice vote. On June 7, 2017, the full Committee 
on Energy and Commerce met in open markup session and ordered 
H.R. 1222, as amended, favorably reported to the House by a 
voice vote.

                            Committee Votes

    Clause 3(b) of rule XIII requires the Committee to list the 
record votes on the motion to report legislation and amendments 
thereto. There were no record votes taken in connection with 
ordering H.R. 1222 reported.

                 Oversight Findings and Recommendations

    Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of 
rule XIII, the Committee has not held hearings on this 
legislation.

   New Budget Authority, Entitlement Authority, and Tax Expenditures

    Pursuant to clause 3(c)(2) of rule XIII, the Committee 
finds that H.R. 1222 would result in no new or increased budget 
authority, entitlement authority, or tax expenditures or 
revenues.

                  Congressional Budget Office Estimate

    Pursuant to clause 3(c)(3) of rule XIII, the following is 
the cost estimate provided by the Congressional Budget Office 
pursuant to section 402 of the Congressional Budget Act of 
1974.

                                     U.S. Congress,
                               Congressional Budget Office,
                                Washington, DC, September 22, 2017.
Hon. Greg Walden,
Chairman, Committee on Energy and Commerce,
House of Representatives, Washington, DC.
    Dear Mr. Chairman: The Congressional Budget Office has 
prepared the enclosed cost estimate for H.R. 1222, the 
Congenital Heart Futures Reauthorization Act of 2017.
    If you wish further details on this estimate, we will be 
pleased to provide them. The CBO staff contact is Rebecca Yip.
            Sincerely,
                                                        Keith Hall.
    Enclosure.

H.R. 1222--Congenital Heart Futures Reauthorization Act of 2017

    Summary: H.R. 1222 would direct the Secretary of Health and 
Human Services (HHS), through the Centers for Disease Control 
and Prevention (CDC), to enhance surveillance capabilities to 
track the epidemiology of congenital heart disease (CHD) and to 
provide grants to study the epidemiology of CHD across the 
lifespan. In addition, the legislation would require the 
Secretary to produce a report to Congress on CHD that includes 
information on the demographics and health care utilization of 
individuals with the disease. H.R. 1222 would authorize the 
appropriation of a total of $20 million for fiscal years 2018 
through 2022 to carry out those activities. Additionally, the 
bill would reauthorize research on CHD at the National 
Institutes of Health (NIH) and would require NIH to produce a 
report on its research efforts on CHD. CBO estimates that 
implementing all the provisions in H.R. 1222 would cost $131 
million over the 2018-2022 period, assuming appropriation of 
the necessary and specified amounts. Pay-as-you-go procedures 
do not apply to this legislation because it would not affect 
direct spending or revenues.
    CBO estimates that enacting H.R. 1222 would not increase 
net direct spending or on-budget deficits in any of the four 
consecutive 10-year periods beginning in 2028.
    H.R. 1222 contains no intergovernmental or private-sector 
mandates as defined in the Unfunded Mandates Reform Act (UMRA) 
and would impose no costs on state, local, or tribal 
governments.
    Estimated cost to the Federal Government: The estimated 
budgetary effect of H.R. 1222 is shown in the following table. 
The costs of this legislation fall within budget function 550 
(health).

----------------------------------------------------------------------------------------------------------------
                                                          By fiscal year, in millions of dollars--
                                          ----------------------------------------------------------------------
                                             2017      2018      2019      2020      2021      2022    2017-2022
----------------------------------------------------------------------------------------------------------------
                                 INCREASES IN SPENDING SUBJECT TO APPROPRIATION
 
Estimated Authorization Level............         0         4         4         4       115       118        246
Estimated Outlays........................         0         2         4         4        30        93        131
----------------------------------------------------------------------------------------------------------------
Note: Components may not add to totals because of rounding.

    Basis of estimate: H.R. 1222 would direct the Secretary of 
HHS to enhance surveillance capabilities, create a public 
education campaign, and provide grants to study congenital 
heart disease. In 2017, $4 million was authorized for those 
activities at CDC related to CHD. The bill would require CDC to 
build upon current activities by expanding surveillance 
activities and providing a report to Congress that examines CHD 
epidemiology focusing on demographics, healthcare utilization, 
and outcome measures. H.R. 1222 would authorize $4 million for 
each of fiscal years 2018 through 2022 to carry out those 
activities. Based on historical spending for similar 
activities, CBO estimates that implementing those provisions 
would cost $17 million over the 2018-2022 period, primarily for 
additional staff and other administrative costs.
    The bill would also reauthorize NIH to conduct research on 
CHD and would require NIH to report on those efforts. Under 
current law, research at NIH is authorized through fiscal year 
2020. In fiscal year 2016, NIH supported about $111 million in 
research on CHD. Although H.R. 1222 does not specify an 
authorized amount for that research, CBO expects that NIH would 
devote similar amounts of resources in fiscal years 2021 and 
2022. Based on historical spending for similar activities, CBO 
estimates that subject to appropriation of the necessary 
amounts, implementing those provisions would cost $115 million 
over the 2018-2022 period, primarily for research on CHD in 
2021 and 2022.
    Pay-As-You-Go Considerations: None.
    Increase in long-term direct spending and deficits: CBO 
estimates that enacting H.R. 1222 would not increase net direct 
spending or on-budget deficits in any of the four consecutive 
10-year periods beginning in 2028.
    Intergovernmental and private-sector impact: H.R. 1222 
contains no intergovernmental or private-sector mandates as 
defined in UMRA.
    Estimate prepared by: Federal Costs: Rebecca Yip, Ellen 
Werble; Impact on state, local, and tribal governments: Zachary 
Byrum; Impact on the private sector: Amy Petz.
    Estimate approved by: Holly Harvey, Deputy Assistant 
Director for Budget Analysis.

                       Federal Mandates Statement

    The Committee adopts as its own the estimate of Federal 
mandates prepared by the Director of the Congressional Budget 
Office pursuant to section 423 of the Unfunded Mandates Reform 
Act.

         Statement of General Performance Goals and Objectives

    Pursuant to clause 3(c)(4) of rule XIII, the general 
performance goal or objective of this legislation is to enhance 
and further coordinate CHD research, surveillance, and outreach 
initiatives in order to better understand the epidemiology of 
CHD from birth to adulthood and to identify CHD causes, 
outcomes, treatments, and barriers to care.

                    Duplication of Federal Programs

    Pursuant to clause 3(c)(5) of rule XIII, no provision of 
H.R. 1222 is known to be duplicative of another Federal 
program, including any program that was included in a report to 
Congress pursuant to section 21 of Public Law 111-139 or the 
most recent Catalog of Federal Domestic Assistance.

                        Committee Cost Estimate

    Pursuant to clause 3(d)(1) of rule XIII, the Committee 
adopts as its own the cost estimate prepared by the Director of 
the Congressional Budget Office pursuant to section 402 of the 
Congressional Budget Act of 1974.

       Earmark, Limited Tax Benefits, and Limited Tariff Benefits

    Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the 
Committee finds that H.R. 1222 contains no earmarks, limited 
tax benefits, or limited tariff benefits.

                  Disclosure of Directed Rule Makings

    Pursuant to section 3(i) of H.Res. 5, the Committee finds 
that H.R. 1222 contains no directed rule makings.

                      Advisory Committee Statement

    No advisory committees within the meaning of section 5(b) 
of the Federal Advisory Committee Act were created by this 
legislation.

                  Applicability to Legislative Branch

    The Committee finds that the legislation does not relate to 
the terms and conditions of employment or access to public 
services or accommodations within the meaning of section 
102(b)(3) of the Congressional Accountability Act.

             Section-by-Section Analysis of the Legislation

Section 1. Short title

    Section 1 provides that the Act may be cited as the 
``Congenital Heart Futures Reauthorization Act of 2017.''

Section 2. National Congenital Heart Disease Surveillance System

    Section 2 authorizes the appropriation of $4 million for 
each of fiscal years 2018 to 2022 for the Secretary to enhance 
and expand research and surveillance efforts in order to study 
and track the epidemiology, health disparities, and health 
outcomes of congenital heart disease.

Section 3. Congenital heart disease research

    Section 3 authorizes the Director of the National 
Institutes of Health to expand, intensify, and coordinate 
research with respect to congenital heart disease.

         Changes in Existing Law Made by the Bill, as Reported

  In compliance with clause 3(e) of rule XIII of the Rules of 
the House of Representatives, changes in existing law made by 
the bill, as reported, are shown as follows (existing law 
proposed to be omitted is enclosed in black brackets, new 
matter is printed in italic, and existing law in which no 
change is proposed is shown in roman):

                       PUBLIC HEALTH SERVICE ACT

           *       *       *       *       *       *       *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE

           *       *       *       *       *       *       *

PART P--ADDITIONAL PROGRAMS

           *       *       *       *       *       *       *

[SEC. 399V-2. NATIONAL CONGENITAL HEART DISEASE SURVEILLANCE SYSTEM.

  [(a) In General.--The Secretary, acting through the Director 
of the Centers for Disease Control and Prevention, may--
          [(1) enhance and expand infrastructure to track the 
        epidemiology of congenital heart disease and to 
        organize such information into a nationally-
        representative, population-based surveillance system 
        that compiles data concerning actual occurrences of 
        congenital heart disease, to be known as the ``National 
        Congenital Heart Disease Surveillance System''; or
          [(2) award a grant to one eligible entity to 
        undertake the activities described in paragraph (1).
  [(b) Purpose.--The purpose of the Congenital Heart Disease 
Surveillance System shall be to facilitate further research 
into the types of health services patients use and to identify 
possible areas for educational outreach and prevention in 
accordance with standard practices of the Centers for Disease 
Control and Prevention.
  [(c) Content.--The Congenital Heart Disease Surveillance 
System--
          [(1) may include information concerning the incidence 
        and prevalence of congenital heart disease in the 
        United States;
          [(2) may be used to collect and store data on 
        congenital heart disease, including data concerning--
                  [(A) demographic factors associated with 
                congenital heart disease, such as age, race, 
                ethnicity, sex, and family history of 
                individuals who are diagnosed with the disease;
                  [(B) risk factors associated with the 
                disease;
                  [(C) causation of the disease;
                  [(D) treatment approaches; and
                  [(E) outcome measures, such that analysis of 
                the outcome measures will allow derivation of 
                evidence-based best practices and guidelines 
                for congenital heart disease patients; and
          [(3) may ensure the collection and analysis of 
        longitudinal data related to individuals of all ages 
        with congenital heart disease, including infants, young 
        children, adolescents, and adults of all ages.
  [(d) Public Access.--The Congenital Heart Disease 
Surveillance System shall be made available to the public, as 
appropriate, including congenital heart disease researchers.
  [(e) Patient Privacy.--The Secretary shall ensure that the 
Congenital Heart Disease Surveillance System is maintained in a 
manner that complies with the regulations promulgated under 
section 264 of the Health Insurance Portability and 
Accountability Act of 1996.
  [(f) Eligibility for Grant.--To be eligible to receive a 
grant under subsection (a)(2), an entity shall--
          [(1) be a public or private nonprofit entity with 
        specialized experience in congenital heart disease; and
          [(2) submit to the Secretary an application at such 
        time, in such manner, and containing such information 
        as the Secretary may require.]

SEC. 399V-2. NATIONAL CONGENITAL HEART DISEASE RESEARCH, SURVEILLANCE, 
                    AND AWARENESS.

  (a) In General.--The Secretary shall--
          (1) enhance and expand research and surveillance 
        infrastructure to study and track the epidemiology of 
        congenital heart disease (in this section referred to 
        as ``CHD''); and
          (2) award grants to eligible entities to undertake 
        the activities described in this section.
  (b) National Congenital Heart Disease Study.--
          (1) In general.--The Secretary shall plan, develop, 
        implement, and submit one or more reports to the 
        Congress on a study to improve understanding of the 
        epidemiology of CHD across the lifespan, from birth to 
        adulthood, with particular interest in the following:
                  (A) Health care utilization of those affected 
                by CHD.
                  (B) Demographic factors associated with CHD, 
                such as age, race, ethnicity, gender, and 
                family history of individuals who are diagnosed 
                with the disease.
                  (C) Outcome measures, such that analysis of 
                the outcome measures will allow derivation of 
                evidence-based best practices and guidelines 
                for CHD patients.
          (2) Permissible considerations.--The study under this 
        subsection may--
                  (A) gather data on the health outcomes of a 
                diverse population of those affected by CHD;
                  (B) consider health disparities among those 
                affected by CHD, which may include the 
                consideration of prenatal exposures; and
                  (C) incorporate behavioral, emotional, and 
                educational outcomes of those affected by CHD.
          (3) Public access.--Data generated from the study 
        under this subsection shall be made available--
                  (A) for purposes of CHD research, subject to 
                appropriate protections of personal privacy, 
                including protections required by paragraph 
                (4); and
                  (B) to the public, subject to paragraph (4) 
                and with appropriate exceptions for protection 
                of personal privacy.
          (4) Patient privacy.--The Secretary shall ensure that 
        the study under this subsection is carried out in a 
        manner that complies with the requirements applicable 
        to a covered entity under the regulations promulgated 
        pursuant to section 264(c) of the Health Insurance 
        Portability and Accountability Act of 1996.
  (c) Eligibility for Grants.--To be eligible to receive a 
grant under subsection (a)(2), an entity shall--
          (1) be a public or private nonprofit entity with 
        specialized experience in CHD; and
          (2) submit to the Secretary an application at such 
        time, in such manner, and containing such information 
        as the Secretary may require.
  (d) Authorization of Appropriations.--To carry out this 
section, there is authorized to be appropriated $4,000,000 for 
each of fiscal years 2018 through 2022.

           *       *       *       *       *       *       *

TITLE IV--NATIONAL RESEARCH INSTITUTES

           *       *       *       *       *       *       *

Part C--Specific Provisions Respecting National Research Institutes

           *       *       *       *       *       *       *

Subpart 2--National Heart, Lung, and Blood Institute

           *       *       *       *       *       *       *

[SEC. 425. CONGENITAL HEART DISEASE.

  [(a) In General.--The Director of the Institute may expand, 
intensify, and coordinate research and related activities of 
the Institute with respect to congenital heart disease, which 
may include congenital heart disease research with respect to--
          [(1) causation of congenital heart disease, including 
        genetic causes;
          [(2) long-term outcomes in individuals with 
        congenital heart disease, including infants, children, 
        teenagers, adults, and elderly individuals;
          [(3) diagnosis, treatment, and prevention;
          [(4) studies using longitudinal data and 
        retrospective analysis to identify effective treatments 
        and outcomes for individuals with congenital heart 
        disease; and
          [(5) identifying barriers to life-long care for 
        individuals with congenital heart disease.
  [(b) Coordination of Research Activities.--The Director of 
the Institute may coordinate research efforts related to 
congenital heart disease among multiple research institutions 
and may develop research networks.
  [(c) Minority and Medically Underserved Communities.--In 
carrying out the activities described in this section, the 
Director of the Institute shall consider the application of 
such research and other activities to minority and medically 
underserved communities.]

SEC. 425. CONGENITAL HEART DISEASE.

  (a) In General.--The Director of the Institute may expand, 
intensify, and coordinate research and related activities of 
the Institute with respect to congenital heart disease, which 
may include congenital heart disease research with respect to--
          (1) causation of congenital heart disease, including 
        genetic causes;
          (2) long-term outcomes in individuals with congenital 
        heart disease, including infants, children, teenagers, 
        adults, and elderly individuals;
          (3) diagnosis, treatment, and prevention;
          (4) studies using longitudinal data and retrospective 
        analysis to identify effective treatments and outcomes 
        for individuals with congenital heart disease; and
          (5) identifying barriers to lifelong care for 
        individuals with congenital heart disease.
  (b) Coordination of Research Activities.--The Director of the 
Institute may coordinate research efforts related to congenital 
heart disease among multiple research institutions and may 
develop research networks.
  (c) Minority and Medically Underserved Communities.--In 
carrying out the activities described in this section, the 
Director of the Institute shall consider the application of 
such research and other activities to minority and medically 
underserved communities.
  (d) Report From NIH.--Not later than one year after the date 
of the enactment of the Congenital Heart Futures 
Reauthorization Act of 2017, the Director of NIH, acting 
through the Director of the Institute, shall provide a report 
to Congress--
          (1) outlining the ongoing research efforts of the 
        National Institutes of Health regarding congenital 
        heart disease; and
          (2) identifying--
                  (A) future plans for research regarding 
                congenital heart disease; and
                  (B) the areas of greatest need for such 
                research.

           *       *       *       *       *       *       *

                                  [all]
```